JOHNSON & JOHNSON

Member Only Articles

AI Health Factor Performance Trends

Latest Insights

21 February, 2025
Johnson & Johnson Faces Crucial Bankruptcy Hearing Over $10 Billion Proposal to Settle Ovarian Cancer Lawsuits Amid Controversy
Read More >>
20 February, 2025
Johnson & Johnson Achieves High Valuation Scores Amidst Strong Drug Sales and Strategic Acquisitions in the Evolving Pharmaceutical Landscape
Johnson & Johnson (JNJ) has recently ranked favorably in Validea's Multi-Factor Investor model, achieving a 68% score based on its financial fundamentals and valuation criteria. This model emphasizes ...
Read More
19 February, 2025
Johnson & Johnson Emerges as a Resilient Investment with Strong Earnings Growth and Strategic Acquisitions Amid Economic Fluctuations
Johnson & Johnson (JNJ) has solidified its reputation as one of the safest investments in the Dow Jones Industrial Average, highlighted by its impressive AAA credit rating and recent financial perform...
Read More
16 February, 2025
Johnson & Johnson and Sanofi Discontinue Phase III E. Coli Vaccine Study Due to Efficacy Concerns, Resulting in Significant Impairment Charge for Sanofi
Johnson & Johnson has recently faced a significant setback in its vaccine development efforts. On February 15, 2025, it was reported that the company, in partnership with Sanofi, has terminated the Ph...
Read More
15 February, 2025
Johnson & Johnson and Sanofi Discontinue Phase III E. Coli Vaccine Study Due to Efficacy Concerns, Resulting in Significant Impairment Charge for Sanofi
Johnson & Johnson has recently faced a significant setback in its vaccine development efforts. On February 15, 2025, it was reported that the company, in partnership with Sanofi, has terminated the Ph...
Read More